In-vivo evaluation in man of a hydrophilic matrix containing propylthiouracil

Journal of Pharmacy and Pharmacology

Volumn 48, Issue 10, 1996, Pages 1023-1026

  Kabanda, Louis ^a   Lefebvre, Romain Adelin ^b   Remon, Jean Paul ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

3,3',5' TRIIODOTHYRONINE; ANTITHYROID AGENT; HYDROXYPROPYLMETHYLCELLULOSE; PROPYLTHIOURACIL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SOLUBILITY; HUMAN; HUMAN EXPERIMENT; HYDROPHILICITY; HYPERTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; SUSTAINED RELEASE PREPARATION;

EID: 0029796234     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1996.tb05894.x     Document Type: Article

References (16)

1. Aungst, B. J., Vessel, E. S., Shapiro, J. R. (1979) Unusual characteristics of the dose-dependent uptake of propylthiouracil by thyroid gland in vivo. Biochem. Pharmacol. 28: 1479-1484
2. Bartle, W. R., Walker, S. E., Silverberg, J. D. H. (1988) Rectal absorption of propylthiouracil. Int. J. Clin. Pharmacol. Ther. Toxicol. 26: 285-287
3. Cooper, D. S., Saxe, V. C., Maloof, F., Rigway, E. C. (1981) Studies of propylthiouracil using a newly developed radioimmunoassay. J. Clin. Endocrinol. Metab. 52: 204-213
4. Greer, M. A., Meihoff, W. C., Studer, H. (1965) Treatment of hyperthyroidism with a single daily dose of propylthiouracil. N. Engl. J. Med. 272: 888-891
5. Gwinup, G. (1978) Prospective randomized comparison of propylthiouracil. J. Am. Med. Assoc. 239: 2457-2459
6. Kabanda, L., Lefebvre, R. A., Van Bree, H. J., Remon, J. P. (1994a) In vitro and in vivo evaluation in dogs and pigs of a hydrophilic matrix containing propylthiouracil. Pharm. Res. 11: 1663-1668
7. Kabanda, L., De Muynck, C., Lefebvre, R. A., Remon, J. P. (1994b) Validation of a HPLC method for the determination of propylthiouracil in plasma. J. Liquid Chromatogr. 17: 2069-2083
8. Kampmann, J. P., Molholm-Hansen, J. E. (1981a) Correlation between antithyroid effect and serum concentrations of propylthiouracil in patients with hyperthyroidism. Br. J. Clin. Pharmacol. 12: 681-686
9. Kampmann, J. P., Molholm-Hansen, J. E. (1981b) Clinical pharmacokinetics of antithyroid drugs. Clin. Pharmacokinet. 6: 401-428
10. Kampmann, J. P., Skovsted, L. (1974) The pharmacokinetics of propylthiouracil. Acta Pharm. Toxicol. 35: 361-369
11. 3 during propylthiouracil treatment of thyrotoxicosis. Acta Endocrinol. 87: 88-94
12. 35S-Antithyroid concentration and organic binding of iodine in the human thyroid. Clin. Endocrinol. 4: 609-615.
13. Shumaker, R. C., Bauxenbaum, H., Thompson, G. A. (1988) Absplots: A Lotus-123 spreadsheet for calculating and plotting drug absorption rates. Pharm. Res. 5: 247-248
14. Sitar, D. S., Hunnighake, D. B. (1975) Pharmacokinetics of propylthiouracil in man after a single oral dose. J. Clin. Endocrinol. Metab. 40: 26-29
15. Sokal, R. R., Rohlf, F. J. (1991) Biometry, 2nd edn, W. H. Freeman and Company, New York, pp 433-434
16. USP XXII, NF XVII 1990, The United States Pharmacopeia, The National Formulary, United States Pharmacopeial Convention, Inc., Rockville, pp 1578-1579